Pfizer Inc. (NYSE: PFE) said in a press statement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency has given its approval for a new four-dose, multi-dose vial presentation of Prevenar 13. According to the company, its presentation was created to support enhanced efficiency level for health care workers by reducing storage needs significantly apart from cutting down the shipping costs.

Pfizer's Global Medicines Development Group and Medical/Scientific Affairs' Global VP, Luis Jodar, said, "Prevenar 13 is the first approved pneumococcal conjugate vaccine available in a preserved multi-dose vial presentation."

The company's VP also said, "With this new presentation, a box that once carried enough vaccine to help protect 50 infants and children will potentially vaccinate 200, helping to ensure Prevenar 13 is accessible in the most remote regions of the world where the greatest burden of invasive pneumococcal disease lies."

Pfizer indicated its plan to submit its presentation to the World Health Organization (WHO) for prequalification. As and when approved, it will allow the global use of this new presentation of Prevenar.

Shares are up 3.7 percent on the day.

See more from Benzinga

• Mylan Rolls Out Generic Version Of Epivir Tablets

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.